
|Videos|June 2, 2019
Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC
Karim Fizazi, MD, PhD, professor and head of the GARD Inpatient Unit, at Institut Gustave Roussy, discusses the impact of darolutamide (ODM-201) on pain and quality of life in patients with nonmetastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
2
Cost-Effectiveness of Perioperative Pembro in Head and Neck Cancer Hinges on PD-L1 Expression
3
FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs
4
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
5




































